Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: A clinical cohort study

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2339-2343

  Dolling, David I ^a   Dunn, David T ^a   Sutherland, Katherine A ^b   Pillay, Deenan ^c   Mbisa, Jean L ^b   Parry, Chris M ^a   Post, Frank A ^d   Sabin, Caroline A ^c   Cane, Patricia A ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Drug resistance mutations; HIV; Naive patients; Protease inhibitors; Virological failure

Indexed keywords

ABACAVIR; ATAZANAVIR; EMTRICITABINE; LAMIVUDINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CD4+ T LYMPHOCYTE; CODON; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT CARE; PREVALENCE; VIRUS ISOLATION; VIRUS LOAD; VIRUS RESISTANCE;

DRUG RESISTANCE MUTATIONS; HIV; NAIVE PATIENTS; PROTEASE INHIBITORS; VIROLOGICAL FAILURE;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUTATION RATE; MUTATION, MISSENSE; OLIGOPEPTIDES; PYRIDINES; TREATMENT FAILURE; UNITED STATES;

EID: 84885953553     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt199     Document Type: Article

References (15)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected AdultsandAdolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (26 March 2013, date last accessed).
2. Williams I, Churchill D, Anderson J et al. British HIVAssociation guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 Suppl 2: 1-85.
3. Zolopa A, Towner W, Butcher D et al. Resistance profile after viral rebound on atazanavir-containing therapy: focus on protease inhibitor-naive subjects in the IMPACT Study (BMS AI424-128). Antivir Ther 2007; 12 Suppl 1: S86 (Abstract 77).
4. Pellegrin I, Breilh D, Ragnaud JM et al. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther 2006; 11: 421-9.
5. Scherrer Au, Ledergerber B, Von Wyl V et al. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PLoS One 2012; 7: e37983.
6. Colonno R, Rose R, McLaren C et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004; 189: 1802-10.
7. Malan DR, Krantz E, David N et al. Efficacyand safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47: 161-7.
8. Cane P, Chrystie I, Dunn D et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331: 1368.
9. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5: 115-24.
10. Johnson VA, Calvez V, Gunthard HF et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156-64.
11. De Oliveira T, Deforche K, Cassol S et al. Anautomatedgenotypingsystem for analysis ofHIV-1 and othermicrobial sequences. Bioinformatics 2005; 21: 3797-800.
12. PI Resistance Notes: Stanford University HIV Drug Resistance Database; 2011. http://hivdb.stanford.edu/DR/PIResiNote.html (26 March 2013, date last accessed).
13. Sutherland KA, Mbisa JL, Cane PA et al. Contribution of the gag gene to variation in susceptibility to protease inhibitors between different strains of HIV-1. Antivir Ther 2012; 17 Suppl 1: A17 (Abstract 9).
14. Vora S, Marcelin AG, Gunthard HF et al. Clinical validation of atazanavir/ ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 2006; 20: 35-40.
15. Bertoli A, Santoro MM, Lorenzini P et al. Different patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing patients. Antivir Ther 2006; 11 Suppl 1: S99 (Abstract 89).